Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Antivirals Market From 2025 To 2029?

In recent times, the antivirals market has witnessed substantial growth. The market, which is projected to escalate from $106.13 billion in 2024 to $114.7 billion in 2025, predicts a compound annual growth rate (CAGR) of 8.1%. Factors such as the prevalence of viral diseases, public health worries, the expiration of patents, and government interventions are reasons behind the growth witnessed in the historic period.

What Is the Projected Market Size of the Antivirals Market?

The size of the antivirals market is predicted to experience robust expansion in the forthcoming years. The market is projected to rise to $153.67 billion by 2029 with an annual compound growth rate (CAGR) of 7.6%. The predicted increase during the forecast period is due to the emergence of new viral risks and global health initiatives. Innovations in technology, telemedicine, digital health, and personalized medicine are some of the key trends expected to emerge during this period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp

Who are the Major Competitors in the Antivirals Market Outlook?

Major companies operating in the antivirals market include AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Argos Distributors Limited, AVI Biopharma International Ltd., Moderna Inc., BioNTech SE, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

What Is Fueling Growth in the Antivirals Market?

The anticipated escalation of the antiviral market is largely due to the growing prevalence of influenza. Commonly referred to as flu, influenza is an easily transmissible respiratory infection instigated by influenza viruses impacting the nose, throat, and lungs. Antivirals, which inhibit the multiplication and dissemination of influenza viruses within the organism, are prescribed for treating this illness. For example, The Centers for Disease Control and Prevention, an American health organization, reported in October 2022 that during the 2021-2022 period, there were 9 million instances of flu illnesses, 4 million flu-related medical appointments, 100,000 flu-related hospital admissions, and 5,000 flu fatalities. Hence, the rising occurrence of influenza is spurring the expansion of the antiviral market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2437&type=smp

Which Antivirals Market Segments Are Growing the Fastest?

The antivirals market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes

3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications

Subsegments:

1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)

2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals

Which Industry Trends Are Shaping the Future of the Antivirals Market?

Leading corporations in the antiviral market are concentrating on the development of innovative solutions like oral antiviral treatments to improve patient adherence, enhance reachability, cut healthcare expenses, and offer more efficient and easy-to-use alternatives for controlling viral diseases. Oral antiviral treatment comprises medication consumed orally to counteract viral infections. They function by restricting the replication and spread of viruses in the body, thereby minimizing the severity and span of the infection. For example, Pfizer, a pharmaceutical firm based in the US, announced in May 2023, the sanction of Paxlovid, establishing it as the first oral antiviral treatment for COVID-19 in adults, approved by the Food and Drug Administration, a government agency in the US. This approval holds immense significance as it introduces a new method for managing COVID-19, especially during the phase where the pandemic is evolving into an endemic stage. Paxlovid is specifically designed for adults experiencing mild-to-moderate COVID-19 and who are at an elevated risk of escalating to severe disease, including hospitalization or death.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Which Countries Are Leading the Antivirals Market?

North America was the largest region in the anti-viral drug therapy market in 2023. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2437

This Report Delivers Insight On:

1. How big is the antivirals market, and how is it changing globally?

2. Who are the major companies in the antivirals market, and how are they performing?

3. What are the key opportunities and risks in the antivirals market right now?

4. Which products or customer segments are growing the most in the antivirals market?

5. What factors are helping or slowing down the growth of the antivirals market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model